相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment
Pilar Lopez-Nieva et al.
ONCOLOGIST (2021)
MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity
Kamal U. Saikh
IMMUNOLOGIC RESEARCH (2021)
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
Fary Diop et al.
HAEMATOLOGICA (2020)
Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia
Neus Gimenez et al.
LEUKEMIA (2020)
Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells
Monica Lopez-Guerra et al.
ONCOGENE (2020)
Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia
Felice Pepe et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Treatment of Chronic Lymphocytic Leukemia
Jan A. Burger
NEW ENGLAND JOURNAL OF MEDICINE (2020)
In Vitro Evaluation of Clinical Candidates of γ-Secretase Inhibitors: Effects on Notch Inhibition and Promoting Beige Adipogenesis and Mitochondrial Biogenesis
Di Huang et al.
PHARMACEUTICAL RESEARCH (2020)
Clinicopathological characterization of chronic lymphocytic leukemia withMYD88mutations: L265P and non-L265P mutations are associated with different features
Wen Shuai et al.
BLOOD CANCER JOURNAL (2020)
Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia
Xiaoya Yun et al.
BIOMARKER RESEARCH (2020)
Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment
Adalgisa Condoluci et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications
Ruben A. L. de Groen et al.
HAEMATOLOGICA (2019)
Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy
Elisabeth Silkenstedt et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib
Eman L. Dadashian et al.
CANCER RESEARCH (2019)
BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation
Daniela Asslaber et al.
CLINICAL CANCER RESEARCH (2019)
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
David P. Steensma et al.
BLOOD (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
MYD88 L265P Mutation in Lymphoid Malignancies
Xinfang Yu et al.
CANCER RESEARCH (2018)
H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
Michael Seiler et al.
NATURE MEDICINE (2018)
Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities
Alexander N. R. Weber et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins
Akihide Yoshimi et al.
CLINICAL CANCER RESEARCH (2017)
New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia
Rupal Tripathi et al.
EXPERT OPINION ON DRUG DISCOVERY (2017)
Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia
Ewelina Zakrzewska et al.
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA (2017)
Mutations in the 3′ untranslated region of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia
Tamara Bittolo et al.
HAEMATOLOGICA (2017)
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations
R. Rosenquist et al.
LEUKEMIA (2017)
Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia
Giulia Fabbri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene
Shu-Chao Qin et al.
BLOOD CANCER JOURNAL (2017)
Mutations in the 3′ untranslated region of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia
Tamara Bittolo et al.
HAEMATOLOGICA (2017)
The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
Gianluca Gaidano et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2017)
Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Michael Hallek
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia
Maciej Putowski et al.
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ (2017)
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mc1-1
M. Larrayoz et al.
LEUKEMIA (2016)
Present and future of personalized medicine in CLL
Emili Montserrat et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2016)
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
Lili Wang et al.
CANCER CELL (2016)
Chronic lymphocytic leukaemia
Lydia Scarfo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins
Stanley Chun-Wei Lee et al.
NATURE MEDICINE (2016)
NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions
Larry Mansouri et al.
SEMINARS IN CANCER BIOLOGY (2016)
Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms
Charlotte K. Brierley et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2016)
The molecular pathogenesis of chronic lymphocytic leukaemia
Giulia Fabbri et al.
NATURE REVIEWS CANCER (2016)
Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group
Sven Estenfelder et al.
BLOOD (2016)
Prognostic relevance of MYD88 mutations in CLL: the jury is still out
Panagiotis Baliakas et al.
BLOOD (2015)
Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B
Manoj K. Kashyap et al.
HAEMATOLOGICA (2015)
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
Priscilla N. Kelly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Non-coding recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2015)
The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia
Silvia Xargay-Torrent et al.
ONCOTARGET (2015)
Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans
Yi Xia et al.
ONCOTARGET (2015)
Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B
Manoj K. Kashyap et al.
HAEMATOLOGICA (2015)
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
Panagiotis Baliakas et al.
BLOOD (2015)
The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells
M. Lopez-Guerra et al.
LEUKEMIA (2015)
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stephan Stilgenbauer et al.
BLOOD (2014)
Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome
Alejandra Martinez-Trillos et al.
BLOOD (2014)
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2014)
Personalized medicine in CLL: Current status and future perspectives
Uri Rozovski et al.
CANCER LETTERS (2014)
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: Targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia
Eric C. Hales et al.
CELLULAR SIGNALLING (2014)
Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts
V. Agnusdei et al.
LEUKEMIA (2014)
Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia
F. Arruga et al.
LEUKEMIA (2014)
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment
Sabina Chiaretti et al.
LEUKEMIA & LYMPHOMA (2014)
Therapeutic modulation of Notch signalling - are we there yet?
Emma R. Andersson et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB
Yulia N. Demchenko et al.
ONCOTARGET (2014)
Toll-like receptors and cancer: MYD88 mutation and inflammation
James Q. Wang et al.
FRONTIERS IN IMMUNOLOGY (2014)
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study
Panagiotis Baliakas et al.
LANCET HAEMATOLOGY (2014)
IMO-8400, an Antagonist of Toll-like Receptors 7, 8, and 9, in Development for Genetically Defined B-Cell Lymphomas: Safety and Activity in Phase 1 and Phase 2 Clinical Trials
Louis Brenner et al.
BLOOD (2014)
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG
Andrea Schnaiter et al.
BLOOD (2013)
Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Ferry A. L. M. Eskens et al.
CLINICAL CANCER RESEARCH (2013)
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
Davide Rossi et al.
BLOOD (2012)
cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation
Rosanna Lau et al.
CELL CYCLE (2012)
The spliceosome as a target of novel antitumour drugs
Sophie Bonnal et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
Davide Rossi et al.
Mediterranean Journal of Hematology and Infectious Diseases (2012)
Integration of B cell responses through Toll-like receptors and antigen receptors
David J. Rawlings et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing
Liying Fan et al.
ACS CHEMICAL BIOLOGY (2011)
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think
Camille Lobry et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Xose S. Puente et al.
NATURE (2011)
Therapeutic antibody targeting of individual Notch receptors
Yan Wu et al.
NATURE (2010)
Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors
Miguel Aste-Amezaga et al.
PLOS ONE (2010)
Regulation of Adaptive Immunity by the Innate Immune System
Akiko Iwasaki et al.
SCIENCE (2010)
Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells
Emanuela Rosati et al.
BLOOD (2009)
Notch signaling in leukemia
Jon C. Aster et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Noncanonical NF-kappa B activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK
Brian J. Zarnegar et al.
NATURE IMMUNOLOGY (2008)
Splicing factor SF3b as a target of the antitumor natural product pladienolide
Yoshihiko Kotake et al.
NATURE CHEMICAL BIOLOGY (2007)
Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations
Kostas Stamatopoulos et al.
BLOOD (2007)
Pladienolides, new substances from culture of Streptomyces platensis Mer-11107 I.: Taxonomy, fermentation, isolation and screening
T Sakai et al.
JOURNAL OF ANTIBIOTICS (2004)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
